Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4285 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-4285 | EXPERIMENTAL | Participants will be administered ALN-4285 subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered placebo SC |
| Name | Type | Description |
|---|---|---|
| ALN-4285 | DRUG | ALN-4285 will be administered SC |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2 * Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)...
ALN-4285 is an investigational small molecule being developed by Alnylam Pharmaceuticals for use in healthy volunteers. It is currently in Phase 1 clinical development, with an active trial evaluating its safety and tolerability in adult healthy volunteers.
ALN-4285 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company is currently conducting a Phase 1 study of ALN-4285 in healthy volunteers.
ALN-4285 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in adult healthy volunteers.
ALN-4285 is being studied in a single Phase 1 clinical trial with the identifier NCT07295717. The study, titled "A Study to Evaluate ALN-4285 in Adult Healthy Volunteers," is recruiting participants in the United Kingdom and is expected to enroll 76 healthy volunteers.
Yes, the Phase 1 trial of ALN-4285 is randomized, double-blind, and placebo-controlled. This design is used to assess the safety and tolerability of the drug compared to placebo in healthy adult volunteers.